GoodRx Holdings, Inc. released its financial results for the second quarter of 2025, reporting total revenue of $203.1 million, a 1% increase year-over-year, which was in line with previous guidance. However, Prescription Transactions revenue decreased 3% to $143.1 million.
The decline in Prescription Transactions revenue was primarily driven by a 14% decrease in Monthly Active Consumers, attributed to broader changes in the retail pharmacy landscape, including store closures, and a volume reduction in one of its integrated savings programs. Subscription revenue also decreased 7% to $20.5 million.
In contrast, Pharma Manufacturer Solutions revenue continued its strong performance, increasing 32% year-over-year to $35.0 million, driven by organic growth and expanded market penetration. Net income for the quarter was $12.8 million, an increase from $6.7 million in Q2 2024.
Adjusted EBITDA for the quarter was $69.4 million, up from $65.4 million in the prior year, with an Adjusted EBITDA Margin of 34.2%. The company repurchased 10.2 million shares for $46.4 million during the quarter.
For the full year 2025, GoodRx now anticipates Adjusted EBITDA between $265 million and $275 million, a reduction from its previous guidance of $273 million to $287 million. This revised outlook incorporates an estimated $35 million to $40 million revenue loss due to the Rite Aid bankruptcy and volume reduction in an integrated savings program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.